Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Opposition Party Wants Compulsory Licenses For ‘Extortionate’ Medicines

Cystic Fibrosis Drug Orkambi Would Be First In Line

Executive Summary

The UK’s main opposition party says it would use compulsory licensing to ensure access to “extortionately” priced medicines. Unsurprisingly, the responses are polarized.

You may also be interested in...



UK Labour Government Would De-Link Innovation & Drug Pricing

The Labour Party says it would overhaul the system for pricing medicines in the UK by de-linking innovation and price incentives if it gets into office at the next general election.

UK Opposition Party Plans State Owned Generics Company

The UK’s main opposition party is proposing to create a publicly owned generics company, should it win the next general election.

Blog: No Easy Cure For Britain’s Brexit Madness

Prime Minister Boris Johnson has until 19 October to agree a deal, or otherwise must ask for another Brexit extension. But he's in no mood to follow the rules.

Related Content

Topics

UsernamePublicRestriction

Register

PS140905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel